Arnie Clarke achieves revocation of Copaxone patent

On 14th October 2015, Teva Pharmaceutical Industries’ European Patent EP 2 177 528 was revoked. The patent was one of a family of patents covering Copaxone® (glatiramer acetate injection), its intermediates and processes for its production. Global Copaxone® franchise sales were $4.2 billion in 2014. The opposition was filed by...

Read more

Will changes to the Community Trade Mark Regulation reduce the scope of your protection?

At some as-yet unspecified time in 2016 there will be changes to the Community Trade Mark (CTM) Regulation that could reduce the scope of protection of your CTMs. It is important to ensure that your CTMs have been analysed to ensure that you will not suffer a loss of rights...

Read more

Fruitful outcome for patentees in the latest ‘Broccoli’ and ‘Tomato’ cases

The recently-issued Enlarged Board of Appeal (EBA) decisions on two related referrals – “Tomatoes II” (G2/12) and “Broccoli II” (G3/12) – clarify that the exclusion from patentability of essentially biological processes for the production of plants does not extend to product claims directed to the corresponding plants or plant material....

Read more